IL-17 homologous polypeptides and therapeutic uses thereof
View Patent ↗The present invention is directed to novel polypeptides having sequence identity with IL-17 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders.
1. An isolated nucleic acid molecule which comprises DNA having at least 95% nucleic acid sequence identity to:
(a) a nucleotide sequence that encodes amino acid residues 1 to 197 of SEQ ID NO:3,
(b) a nucleotide sequence that encodes amino acid residues 19 to 197 of SEQ ID NO:3,
(c) the nucleotide sequence from position 50 to 640 of SEQ ID NO:4,
(d) the nucleotide sequence from position 104 to 640 of SEQ ID NO:4,
(e) the full-length coding sequence of the cDNA deposited under ATCC accession number 203552, or
(f) the full-length coding sequence of the cDNA deposited under ATCC accession number 203552 lacking its associated signal peptide encoding region; wherein said isolated nucleic acid molecule encodes a polypeptide capable of inducing the production of TNF-α in human leukemia monocytic THP-1 cells.
2. The isolated nucleic acid molecule of claim 1 which comprises DNA encoding amino acid residues 1 to 197 of SEQ ID NO:3.
3. The isolated nucleic acid molecule of claim 1 which comprises DNA encoding amino acid residues 19 to 197 of SEQ ID NO:3.
4. The isolated nucleic acid molecule of claim 1 which comprises the nucleotide sequence from position 50 to 640 of SEQ ID NO:4.
5. The isolated nucleic acid molecule of claim 1 which comprises the nucleotide sequence from position 104 to 640 of SEQ ID NO:4.
6. The isolated nucleic acid molecule of claim 1 which comprises the full-length coding sequence of the cDNA deposited under ATCC accession number 203522.
7. The isolated nucleic acid molecule of claim 1 which comprises the full-length coding sequence of the cDNA deposited under ATCC accession number 203522 lacking its associated signal peptide encoding region.
8. A vector comprising the isolated nucleic acid molecule of claim 1 .
9. A host cell comprising the vector of claim 8 .
10. The host cell of claim 9 which is a CHO cell, an E. coli , a yeast cell or an insect cell comprising a Baculovirus expression vector.
11. A process for producing a polypeptide having at least 95% amino acid sequence identity to SEQ ID NO:3, wherein said process comprises culturing the host cell of claim 9 under conditions suitable for expression of said polypeptide and recovering said polypeptide from the cell culture.
12. An isolated nucleic acid molecule which comprises:
(a) a nucleotide sequence that encodes amino acid residues 1 to 197 of SEQ ID NO:3,
(b) a nucleotide sequence that encodes amino acid residues 19 to 197 of SEQ ID NO:3,
(c) the nucleotide sequence from position 50 to 640 of SEQ ID NO:4,
(d) the nucleotide sequence from position 104 to 640 of SEQ ID NO:4,
(e) the full-length coding sequence of the cDNA deposited under ATCC accession number 203552, or
(f) the full-length coding sequence of the cDNA deposited under ATCC accession number 203552 lacking its associated signal peptide encoding region.